Skip to main content

Table 3 Response and survival by PD-L1 expression

From: SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

Endpoint, na (%)PD-L1 TC ≥ 25%PD-L1 TC < 25%PD-L1 TC ≥ 10%PD-L1 TC < 10%PD-L1 TC ≥ 50%PD-L1 TC < 50%
From diagnosis date to death
 Median OS, months (range)8.2 (6.3–10.6)10.1 (8.3–12.2)9.6 (7.5–12.5)9.4 (7.9–11.4)7.9 (5.5–12.4)10.0 (8.5–11.8)
 log-rank P value, PD-L1 high vs PD-L1 low/negative0.550.320.39
From first-line therapy
 Number evaluable2570    
 ORRb, n (%)
 Overall response rate10 (40.0)31 (44.3)    
 Complete response0 (0.0)1 (1.4)    
 Partial response10 (40.0)30 (42.9)    
 Duration of response, n824    
 Median, weeks (range)10.6 (0.1–28.7)15.3 (1.7–52.3)    
 PFS, n7316911013241201
Median, months (range)4.2 (2.6–4.8)4.8 (3.9–5.8)4.4 (3.3–4.9)4.9 (3.9–6.0)4.8 (3.2–6.1)4.5 (3.9–5.0)
log-rank P value, PD-L1 high vs PD-L1 low/negative0.370.540.56
From second-line therapy
 Number evaluable1018    
 ORRb, n (%)
 Overall response rate2 (20.0)1 (5.6)    
 Complete response0 (0.0)0 (0.0)    
 Partial response2 (20.0)1 (5.6)    
 Duration of response, n21    
 Median, weeks (range)10.6 (5.9–15.4)1.3 (1.3–1.3)    
 PFS, n255838451370
 Median, months (range)4.1 (2.8–7.1)2.2 (1.6–4.0)4.1 (2.2–6.5)2.1 (1.6–3.6)6.3 (1.2–13.8)2.4 (1.6–3.8)
 log-rank P value, PD-L1 high vs PD-L1 low/negative0.040.040.03
  1. aPatients with PD-L1 result N = 396
  2. bORR measured by RESIST
  3. ORR objective response rate, OS overall survival, PD-L1 programmed cell death-ligand 1, PFS progression-free survival, RECIST Response Evaluation Criteria In Solid Tumors